A Case of Metastatic Fumarate Hydratase-Deficient–like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

Sekito, Takanori; Takamoto, Atsushi; Kobayashi, Yasuyuki; Mitsui, Masao; Watari, Shogo; Kubota, Risa; Sadahira, Takuya; Iwata, Takehiro; Nishimura, Shingo; Edamura, Kohei; Sako, Tomoko; Araki, Motoo; Watanabe, Masami; Watanabe, Toyohiko; Shibata, Rei; Ennishi, Daisuke; Nasu, Yasutomo

ID	62237
JaLCDOI	10.18926/AMO/62237
フルテキストURL	75_3_397.pdf 5.98 MB
著者	Sekito, Takanori Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Takamoto, Atsushi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kobayashi, Yasuyuki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Mitsui, Masao Department of Urology, Kurashiki Medical Center Watari, Shogo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kubota, Risa Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Sadahira, Takuya Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Iwata, Takehiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Nishimura, Shingo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Edamura, Kohei Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Sako, Tomoko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Watanabe, Masami Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Watanabe, Toyohiko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Shibata, Rei Department of Pathology, Okayama University Hospital Ennishi, Daisuke Department of Hematology and Oncology, Okayama University Hospital Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録	We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/ Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.
キーワード	fumarate hydratase fumarate hydratase-deficient renal cell carcinoma renal cell carcinoma ipilimumab nivolumab
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2021-06
巻	75巻
号	3号
出版者	Okayama University Medical School
開始ページ	397
終了ページ	402
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2021 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	34176946
Web of Science KeyUT	000667147700017
NAID	120007089822